Effects of empagliflozin on left ventricular diastolic function in addition to usual care in individuals with type 2 diabetes mellitus—results from the randomized, double-blind, placebo-controlled EmDia trial

BACKGROUND: The sodium-glucose co-transporter 2 inhibitor empagliflozin improves cardiovascular outcome in patients with type 2 diabetes mellitus (T2DM) and heart failure. Experimental studies suggest a direct cardiac effect of empagliflozin associated with an improvement in left ventricular diastol...

Descripción completa

Detalles Bibliográficos
Autores principales: Prochaska, Jürgen H., Jünger, Claus, Schulz, Andreas, Arnold, Natalie, Müller, Felix, Heidorn, Marc William, Baumkötter, Rieke, Zahn, Daniela, Koeck, Thomas, Tröbs, Sven-Oliver, Lackner, Karl J., Daiber, Andreas, Binder, Harald, Shah, Sanjiv J., Gori, Tommaso, Münzel, Thomas, Wild, Philipp S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293456/
https://www.ncbi.nlm.nih.gov/pubmed/36763159
http://dx.doi.org/10.1007/s00392-023-02164-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293456/
https://www.ncbi.nlm.nih.gov/pubmed/36763159
http://dx.doi.org/10.1007/s00392-023-02164-w

Ejemplares similares